newsfilter
← Latest News
GlobeNewswire·

BriaCell Presents Positive Clinical Data at ASCO 2026

Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, which